AMN / WEB DESK
Bharat Biotech Chief Managing Director Dr Krishna Ella today slammed the criticism against the Indian vaccine for COVID-19, called Covaxin and its emergency approval. Addressing a virtual press conference this evening, he said, the Covaxin developed by the Bharat Biotech Limited is in no way inferior to the other vaccines developed by other countries like Pfizer. He said, the efficacy data is not available right now and the third phase trial data will be revealed by February or March.
Speaking about the criticism by many companies and media against the emergency approval given to Covaxin, he said, the approvals have been granted on the basis of conditions set up by the Central Drugs Standard Control Organisation (CDSCO). He said, all standards were maintained for the development of vaccines.
He said, 23 thousand people have been vaccinated during the Third Phase trial and the Covaxin is ready to be rolled out. He said, seven billion doses of COVAXIN will be produced soon from their four units including three in Hyderabad and one in Bangaluru of the Bharat Biotech.
It may be recalled that the Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR), has developed COVID-19 inactivated vaccine called Covaxin and got approval for emergency use by the Drug Controller General of India.
Dr Krishna Ella further said, Bharat Biotech will soon take up a trail of an inactivated vaccine on Children soon.